Rare Diseases
& Orphan Drugs
TFS HealthScience – your partner for bringing treatments to patients faster
TFS HealthScience – your partner for bringing treatments to patients faster
TFS HealthScience Rare Diseases and Orphan Drugs has worked with a wide variety of compounds, including small molecules and biologics, across all phases of clinical development and real-world evidence studies. We understand the unique challenges these studies pose and have specific strategies to mitigate risks. These strategies include:
From protocol design to submission of study documents, TFS is a source of top scientific, medical, regulatory, and operational expertise. The quality of our full-service portfolio is built on the expertise of our team: scientific advisors, regulatory strategists, and research professionals, all focused on your project’s success.
Investigator identification and patient recruitment are critical in an orphan drug clinical trial and this is magnified when a trial is failing. This complex Phase III trial for hypoparathyroidism was being conducted across Central/Eastern Europe and North America. The incumbent international CRO was unable to meet the enrolment timelines and costs were escalating. Of the target patient enrolment, approximately 95% had yet to be identified when TFS assumed full-service responsibility for this study.
TFS Rare Diseases and Orphan Drugs created a business unit to enhance and augment the already strong experience and expertise in this area. With our dedicated rare disease project managers and physicians, we then craft a team from TFS therapeutic and functional groups that has the experience you need, when and where you need it.
We are ready to partner with you to face the challenges posed by rare diseases. Whichever service we provide, we’re on your team.